Pedmark (Sodium Thiosulfate)
Prevention of Cisplatin-Induced Ototoxicity in pediatric localized solid tumors
Key Facts
About Fennec Pharmaceuticals
Fennec Pharmaceuticals is a commercial-stage biotech with a focused mission: to prevent cisplatin-induced hearing loss (CIO), a severe and permanent side effect affecting up to 90% of treated pediatric patients. Its sole asset, Pedmark (sodium thiosulfate injection), received FDA approval in September 2022, marking the first and only approved therapy for this indication. The company's strategy centers on the commercial rollout of Pedmark in the U.S., supported by lifecycle management through label expansion studies and strategic collaborations to drive adoption and address a significant unmet medical need.
View full company profileAbout Fennec Pharmaceuticals
Fennec Pharmaceuticals is a commercial-stage biotech with a focused mission: to prevent cisplatin-induced hearing loss (CIO), a severe and permanent side effect affecting up to 90% of treated pediatric patients. Its sole asset, Pedmark (sodium thiosulfate injection), received FDA approval in September 2022, marking the first and only approved therapy for this indication. The company's strategy centers on the commercial rollout of Pedmark in the U.S., supported by lifecycle management through label expansion studies and strategic collaborations to drive adoption and address a significant unmet medical need.
View full company profile